These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18928924)

  • 1. Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone.
    Rossi PJ; Urbanic J; Clark PE; McCullough DL; Lee WR
    Brachytherapy; 2008; 7(4):286-9. PubMed ID: 18928924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)?
    Papagikos MA; Deguzman AF; Rossi PJ; McCullough DL; Clark PE; Lee WR
    Brachytherapy; 2005; 4(4):252-8. PubMed ID: 16344254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone.
    Papagikos MA; Rossi PJ; Urbanic JJ; deGuzman AF; McCullough DL; Clark PE; Lee WR
    Am J Clin Oncol; 2007 Apr; 30(2):199-204. PubMed ID: 17414471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer.
    Rossi PJ; Clark PE; Papagikos MA; McCullough DL; Lee WR
    Urology; 2006 Feb; 67(2):349-53. PubMed ID: 16461084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer control after low-dose-rate prostate brachytherapy performed by a multidisciplinary team with no previous prostate brachytherapy experience.
    McMullen KP; deGuzman AF; McCullough DL; Lee WR
    Urology; 2004 Jun; 63(6):1128-31. PubMed ID: 15183965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosimetry and cancer control after low-dose-rate prostate brachytherapy.
    Robert Lee W; Deguzman AF; McMullen KP; McCullough DL
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):52-9. PubMed ID: 15629593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
    Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of definition of preradiotherapy prostate-specific antigen velocity on its association with prostate cancer-specific mortality and all-cause mortality.
    Nguyen PL; Chen MH; Renshaw AA; Sussman B; D'Amico AV
    Urology; 2007 Aug; 70(2):288-93. PubMed ID: 17826491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer: The Memorial Sloan-Kettering Cancer Center experience.
    Zelefsky MJ; Chou JF; Pei X; Yamada Y; Kollmeier M; Cox B; Zhang Z; Schechter M; Cohen GN; Zaider M
    Brachytherapy; 2012; 11(4):245-9. PubMed ID: 21925957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy.
    Palma D; Tyldesley S; Blood P; Liu M; Morris J; Pickles T;
    Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1425-9. PubMed ID: 17394943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
    Palma D; Tyldesley S; Pickles T;
    Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is prostate-specific antigen percentage decrease predictive of clinical outcome after permanent iodine-125 interstitial brachytherapy for prostate cancer?
    Paoluzzi M; Mignogna M; Lorenzini E; Valent F; Fontana N; Pinzi N; Repetti F; Ponchietti R
    Brachytherapy; 2012; 11(4):277-83. PubMed ID: 22137870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH.
    King CR; Freedland SJ; Terris MK; Aronson WJ; Kane CJ; Amling CL; Presti JC
    Urology; 2007 Apr; 69(4):732-7. PubMed ID: 17445660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age.
    Critz FA; Williams WH; Levinson AK; Benton JB; Schnell FJ; Holladay CT; Shrake PD
    J Urol; 2003 Nov; 170(5):1864-7. PubMed ID: 14532794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate carcinoma.
    Potters L; Purrazzella R; Brustein S; Fearn P; Leibel SA; Kattan MW
    Cancer; 2002 Oct; 95(7):1451-6. PubMed ID: 12237913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
    Ko EC; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database.
    King CR; Freedland SJ; Terris MK; Kane CJ; Amling CL; Aronson WJ; Presti JC
    Urology; 2007 May; 69(5):921-6. PubMed ID: 17482935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.